Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baloxavir susceptibility and household transmission surveillance in pediatric influenza
2023-504672-22-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label trial of baloxavir marboxil in influenza (2 arms), sponsored by Roche. Primary endpoints: Incidence of resistance-associated pre-treatment substitutions at baseline and Incidence of resistance-associated treatment-emergent substitutions. Planned start Nov 2023; status: authorised.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on 2023-504672-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504672-22-00.